chevron-down Created with Sketch Beta.
0

    Jun

    Proving But-for Entry Dates in Pharmaceutical Antitrust Litigation

    12 PM EDT

    A question arises in most pharmaceutical antitrust cases: when would generic entry have occurred absent the accused conduct? In this program, a panel of experienced economists and attorneys who have addressed these issues from discovery to trial will discuss approaches to proving but-for entry dates. They will illustrate the economic models and evidence used to support and dispute entry dates.
    $00
    NON-MEMBERS
    $00
    MEMBERS
    $00
    SECTION MEMBERS
    $00
    YOUR PRICE
    Register Now *Additional discounts may apply at checkout

    Log In to view your rate

    Unlock the discounted member rate

    Join first as a member, and then purchase this product at special member pricing

    Join Now

    The content of this program does not meet requirements for continuing legal education (CLE) accreditation. You will not receive CLE credit for participating.

    Moderator

    • Danielle Foley- Venable LLP

    Speakers

    • Abbye Ognibene- Hagens Berman LLP
    • Archan Ruparel- Charles River Associates
    • Keith Leffler- University of Washington

    Event Details

    Duration

    60

    Format

    Webinar

    Date

    Jun 14, 2024

    2024-06-14T12:00:00-04:00 2024-06-14T13:00:00-04:00 Proving But-for Entry Dates in Pharmaceutical Antitrust Litigation A question arises in most pharmaceutical antitrust cases: when would generic entry have occurred absent the accused conduct? In this program, a panel of experienced economists and attorneys who have addressed these issues from discovery to trial will discuss approaches to proving but-for entry dates. They will illustrate the economic models and evidence used to support and dispute entry dates.

    Sponsors

    Co-sponsors

    Economics

    Health Care and Pharmaceuticals

    Related Products

    Related On-Demand CLE